Merkel Cell Carcinoma Clinical Trials

36 recruitingLast updated: June 17, 2026

There are 36 actively recruiting merkel cell carcinoma clinical trials across 11 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Houston, Texas, United States, Pittsburgh, Pennsylvania, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Merkel Cell Carcinoma Trials at a Glance

36 actively recruiting trials for merkel cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 19 trials, with the heaviest enrollment activity in Houston, Pittsburgh, and New York. Lead sponsors running merkel cell carcinoma studies include Mayo Clinic, M.D. Anderson Cancer Center, and Melanoma Institute Australia.

Browse merkel cell carcinoma trials by phase

Treatments under study

About Merkel Cell Carcinoma Clinical Trials

Looking for clinical trials for Merkel Cell Carcinoma? There are currently 25 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Merkel Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Merkel Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 36 trials

Recruiting
Phase 1Phase 2

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+10 more
National Cancer Institute (NCI)16 enrolled26 locationsNCT05896839
Recruiting
Phase 2

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Merkel Cell CarcinomaMalignant NeoplasmAcquired Immunodeficiency Syndrome+5 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02479698
Recruiting
Phase 1Phase 2

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Triple-Negative Breast CancerMelanomaNon-small Cell Lung Cancer+6 more
AstraZeneca60 enrolled13 locationsNCT07115043
Recruiting
Phase 1

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Triple-Negative Breast CancerPancreatic CancerMelanoma+7 more
Memgen, Inc.40 enrolled2 locationsNCT05076760
Recruiting
Phase 1

A Study of CRD3874-SI in People With Solid Tumors

SarcomaMerkel Cell Carcinoma
Memorial Sloan Kettering Cancer Center81 enrolled7 locationsNCT06021626
Recruiting
Phase 1

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Merkel Cell CarcinomaCutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute36 enrolled1 locationNCT04975152
Recruiting

French National Database of Rare Dermatological Cancers

Merkel Cell CarcinomaAdnexal Tumor of SkinAdvanced Basal Cell Carcinoma Requiring Systemic Treatment
University Hospital, Lille9,000 enrolled34 locationsNCT03210935
Recruiting
Phase 1Phase 2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Cervical CancerMelanomaNon-small Cell Lung Cancer+8 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Phase 1

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Locally Advanced Merkel Cell CarcinomaSmall Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine Cancer+8 more
SystImmune Inc.120 enrolled20 locationsNCT07080242
Recruiting
Phase 2

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Breast CarcinomaUrothelial CarcinomaOvarian Carcinoma+26 more
Mayo Clinic27 enrolled1 locationNCT07285044
Recruiting
Phase 1

A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

Cutaneous MelanomaMerkel Cell Carcinoma of SkinBasal Cell Carcinoma of Skin+2 more
Kupando GmbH21 enrolled2 locationsNCT07600476
Recruiting
Phase 2

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

Merkel Cell Carcinoma
Weill Medical College of Cornell University18 enrolled3 locationsNCT05583708
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2Phase 3

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.118 enrolled18 locationsNCT06947928
Recruiting
Not Applicable

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

Liver CancerMelanomaMerkel Cell Carcinoma+9 more
Istituto Oncologico Veneto IRCCS24 enrolled1 locationNCT06753136
Recruiting
Phase 1

A Study of VET3-TGI in Patients With Solid Tumors

Cervical CancerNon-small Cell Lung CancerHead and Neck Squamous Cell Carcinoma+10 more
KaliVir Immunotherapeutics60 enrolled7 locationsNCT06444815
Recruiting

Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study

Locally Advanced Merkel Cell CarcinomaLocally Advanced Mucosal MelanomaClinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8+5 more
Ohio State University Comprehensive Cancer Center70 enrolled1 locationNCT07215988
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 2

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Skin Squamous Cell CarcinomaMerkel Cell CarcinomaCutaneous Melanoma
Ohio State University Comprehensive Cancer Center100 enrolled1 locationNCT06223659
Recruiting
Phase 1Phase 2

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Colorectal, CancerEsophageal CancerGastric Cancer+18 more
Neonc Technologies, Inc.134 enrolled6 locationsNCT06047379